ASCO 2023 Lung Cancer – Marjorie Zauderer
Marjorie G. Zauderer explains the correlations between histopathological features and genetics in the setting of malignant mesothelioma, and the potential benefit of studying therapeutically relevant subgroups of patients separately, critically discusses trails using PD-1 checkpoint inhibition in unresectable mesothelioma and once again encourages everyone to explore the poster sessions at the major conferences to interact with colleagues around the world.
Here is the full ASCO 2023 Lung Cancer report.
More posts
Targeted approaches in advanced disease
Targeted approaches in advanced disease Anti-EGFR agents plus inserted chemotherapy Ac
Small-cell lung cancer: novel agents & biomarkers
Small-cell lung cancer: novel agents & biomarkers Atezolizumab plus talazoparib as
Early-stage NSCLC: current insights into perioperative strategies
Early-stage NSCLC: current insights into perioperative strategies Overall survival sup
Preface – ASCO Lung Cancer 2023
Preface – ASCO Lung Cancer 2023 © private – Manali I. Patel, MD MPH MS, Associate Pro